Bioventix plc
(“Bioventix” or the “Company”)
Unaudited Interim Results for the six months ended 31 December 2018
Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim financial results for the six-month period ended 31 December 2018.
To download this report as a PDF file click here.
Unaudited interim results for the six months ended 31st December 2018.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
|
|
||
Bioventix plc
(“Bioventix” or “the Company”)
Issue of Equity
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has applied for 1,000 ordinary shares of 5 pence each (the “Option Shares”) to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 4 February 2019.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or the “Company”)
Result of AGM
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.
TR-1: Notification of major interest in shares.